INSERM (Institut National de la Santé et de la Recherche Médicale);Université Nice Sophia Antipolis;Assistance Publique-Hôpitaux de Paris (APHP)
发明人:
申请号：
EP16775236.9
公开号：
EP3356551B1
申请日:
2016.09.29
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The invention relates to an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. The invention also relates to an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.
